Tuftsin-analog peptide

Selank

Selank is a heptapeptide analog of tuftsin with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.1 FDA states it lacks important information on the safety of selank acetate in humans.2

Moderate evidenceGet the app

Level after one dose

Selank after one dose: 50% at ~3 min, 25% at 6 min, 12.5% at 9 min.

Drawn from the half-life in the app's model, ~3 min. The model's figures

Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.1 Volkova and colleagues (Institute of Molecular Genetics, Russian Academy of Sciences), Frontiers in Pharmacology, 2016, describe it as "a synthetic analog of the endogenous tuftsin molecule (the short Thr-Lys-Pro-Arg fragment of the human immunoglobulin G heavy chain)", lengthened at the C terminus with Pro-Gly-Pro "to improve its metabolic stability and yield a relatively longer duration".3

Deigin and colleagues, Pharmaceutics, 2022, list Selank in a table of "Peptide drugs developed in Russia", in the group "Anxiolytic".4 Renke and Chinellato, International Journal of Molecular Sciences, 2026, write of Semax and Selank: "In the rest of the world, they are not approved".5

The app's evidence badge reads Moderate Evidence, which is the app's own grade. Three of the four patient reports state totals of 60, 62 and 70 patients, and the one imaging study enrolled 52 healthy participants.6,7,8,9

The findings below come from cell, tissue and animal work, apart from the patient measurements under human studies. Volkova and colleagues word the GABA mechanism as a hypothesis: "one of its possible molecular mechanisms is associated with allosteric modulation of the GABAergic system".3

GABA receptor findings

Vyunova and colleagues (Institute of Molecular Genetics), Protein and Peptide Letters, 2018, used radioligand binding on isolated brain cell membranes and report: "It was shown that Selank affect the [3H]GABA binding as a positive allosteric modulator".1 Selank "is able to block the modulatory activity of Diazepam and Olanzapine", and the binding sites of the peptide and of those drugs are "apparently not the same" but may partially overlap.1

Volkova and colleagues gave rats a single intranasal dose of Selank or GABA (300 µg/kg, 6 µl) and measured 84 neurotransmission genes in the frontal cortex.3 Each group had 10 rats, half sampled at 1 hour and half at 3 hours.3 They report significant changes in the expression of 45 genes at 1 hour and 22 genes at 3 hours after Selank or GABA: 29 and 17 genes after Selank, 41 and 9 after GABA.3 The positive correlation between the changes after Selank and after GABA was within the 1-hour data only, and at 3 hours it was negative.3 GABA but not Selank changed another 16 genes at 1 hour, which the authors read as suggesting that Selank "acts not directly through the center of the specific binding of GABA".3 The study was supported by a Russian Science Foundation grant (project 16-15-00238), and the authors declare no commercial or financial relationships that could be a conflict of interest.3

In a cell study by Filatova and colleagues, Frontiers in Pharmacology, 2017, human IMR-32 neuroblastoma cells showed a null result for Selank on its own: "We found no changes in the mRNA levels of the genes studied under the effect of Selank".10 They conclude that Selank "has no direct effect on the mRNA levels of the GABAergic system genes" in those cells, while their results "partially confirm the hypothesis that the peptide may affect the interaction of GABA with GABAA receptors".10 The combination of Selank and GABA "led to nearly complete suppression of changes in expression of genes in which mRNA levels changed under the effect of GABA", and the combination of Selank and olanzapine changed 35 of 69 genes, more than olanzapine alone (25 genes).10 The study was supported by a Russian Science Foundation grant (project 16-15-00238), and the authors declare no commercial or financial relationships that could be a conflict of interest.10

Kasian and colleagues, Behavioural Neurology, 2017, gave rats Selank, diazepam or both, with and without unpredictable chronic mild stress, and used the elevated plus maze.11 They report that "even in the absence of chronic stress, the administration of a course of test substances changed anxiety indicators toward their deterioration, but the changes after the administration of a course of Selank were less pronounced".11 They add that Selank alone "was the most effective in reducing elevated levels of anxiety, induced by the administration of a course of test substances", and that under chronic stress the anxiety values after diazepam and Selank together "did not differ from the respective values observed before chronic stress exposure".11 The record states no dose, route, number of animals or funder, and the authors declare no conflict of interests.11

Enkephalin-degrading enzymes

Kost and colleagues, Bioorganicheskaia Khimiia, 2001, report a dose-dependent effect of Selank on the enkephalin-degrading enzymes of human serum in vitro, with an IC50 of 20 microM for Selank and 10 microM for Semax.12 Zolotarev and colleagues, 2004, working with human plasma and tritium-labelled Leu-enkephalin, report that "Selank is more specific for carboxypeptidases and dicarboxypeptidases" than bestatin.13 These are assays on human serum or plasma, not studies in which people were dosed.12,13

Immune and neurotrophin findings in mice and rats

Kolomin and colleagues, Molecular Immunology, 2014, gave mice a single intraperitoneal injection (100 µg/kg) of Selank or its fragment Gly-Pro and measured four spleen genes (C3, Casp1, Il2rg and Xcr1) over time.14 They report "a significant 3-fold decrease in the C3 mRNA level just 30 min after Selank injection", a wave-like alteration in Casp1 mRNA, a significant alteration in Il2rg mRNA at early time points, and an almost equal reduction in Xcr1 mRNA 90 minutes after Selank and Gly-Pro, with similar expression profiles after Selank and Gly-Pro in most cases.14

Kolik and colleagues (Zakusov Research Institute of Pharmacology), Bulletin of Experimental Biology and Medicine, 2019, gave outbred rats, some of them given 10% ethanol as the only fluid for 30 weeks, Selank at 0.3 mg/kg a day for 7 days intraperitoneally, and report that in ex vivo experiments it "prevented ethanol-induced increase in BDNF content in the hippocampus and frontal cortex" (p<0.05).15

Inozemtseva and colleagues, Doklady Biological Sciences, 2008, report in their title that intranasal Selank "regulates BDNF expression in the rat hippocampus in vivo"; the record for that report carries no summary text.16

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3 min
Bioavailability
95%
Typical dose
200–600 mcg
Route
Nasal, SubQ
Time to peak
~3 min

The app lists a half-life of about 3 minutes, a time to peak of about 3 minutes, a bioavailability of 95% and about 8 hours of activity. The records read for these references report no half-life, bioavailability or time to peak for Selank. Zolotarev and colleagues, Bioorganicheskaia Khimiia, 2006, report that the pharmacokinetics of Selank "was also studied in brain tissues using the intranasal in vivo administration of this peptide" and that "The concentrations of labeled peptides were determined"; the record states no values.17

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureReported in the references
Half-lifeAbout 3 minutesThe records read for the references below report no half-life value.
Bioavailability95%The records read report no bioavailability figure.
Time to peakAbout 3 minutesThe records read report no time to peak.
Duration of activityAbout 8 hoursThe records read report no duration in hours. Medvedev and colleagues, 2014, in a 60-patient comparison of Selank with phenazepam: "The anxiolytic effect lasted for a week after last receiving the peptide"; the number given Selank and the schedule are not stated in the record.6
RoutesNasal, SubQIntranasal in rats (Volkova, 2016) and mice (Vasil'eva, 2016); intraperitoneal in mice and rats (Vasil'eva, 2016; Kolomin, 2014; Kolik, 2019). The records read report no subcutaneous administration, and the records of the human reports do not state the route.3,18,14,15
Breakdown productsNot listedZolotarev and colleagues, 2006, studied biodegradation in blood plasma (species not stated): "the pentapeptide TKPRP, tripeptide TKP, and dipeptides RP and GP were shown to be the major products of Selank biodegradation".17

Vasil'eva and colleagues, Eksperimentalnaia i Klinicheskaia Farmakologiia, 2016, gave inbred BALB/c and C57BL/6 mice 300 µg/kg a day for 5 days either intranasally or intraperitoneally.18 Anxiolytic and nootropic efficiency "was observed only in BALB/c mice" by both routes; in BALB/c mice, intraperitoneal Selank raised GABA receptor binding sites in the frontal cortex by 38% without change in NMDA-receptor binding in the hippocampus, while intranasal Selank raised binding sites of MK-801, an NMDA-receptor ligand, by 23% with "no effect on GABA receptors".18 The authors suggest that the differences between routes are determined by "drug pharmacokinetics and biotransformation".18

Ashmarin and colleagues, Pathophysiology, 2005, write that the glyprolines and some other prolyl-glycyl-proline-containing oligopeptides "show the stability quite comparable with those of major pharmacological preparations", and that the ability of glyprolines to pass gastro-enteric tract barriers "opens ways to per-oral administration" of this new group of drugs such as semax, selank and their fragments.19 The record states no oral bioavailability figure for Selank.19

4

Human studies

A PubMed query on 16 November 2026 for selank in titles or summary text returned 68 records; 3 carry the clinical trial or randomized controlled trial publication type (Zozulia and colleagues, 2008, and Medvedev and colleagues, 2014 and 2015). A ClinicalTrials.gov query for the term selank on the same date returned 10 studies, and the word Selank does not appear in the text of any of the 10 records.

Miasoedov (also spelled Myasoedov) NF is an author of all five human reports listed below, of the rat, cell and membrane-binding reports by Volkova, Filatova, Kasian, Kolomin and Vyunova, and of Kost and colleagues, 2001, Zolotarev and colleagues, 2004 and 2006, and Ashmarin and colleagues, 2005.7,6,8,20,9,3,10,11,14,1,12,13,17,19 Volkova and colleagues write that Selank "was designed and produced at the Institute of Molecular Genetics, Russian Academy of Sciences, in cooperation with the V.V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences".3 Medvedev and colleagues, 2015, list Myasoedov's affiliation as the Institute of Molecular Genetics, and Kolik and colleagues, 2019, is from the Zakusov Research Institute of Pharmacology.8,15 None of the records of the human reports names a sponsor or funder.

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Zozulia and colleagues, 20087Comparison of Selank with medazepam; PubMed type randomized controlled trial62 patients with generalized anxiety disorder and neurasthenia (Selank 30, medazepam 32)Not stated in the record"The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects"
Medvedev and colleagues, 20146Comparison of Selank with phenazepam; PubMed type clinical trial60 patients with phobic-anxiety and somatoform disorders (number given Selank not stated)Not stated in the record"Pronounced anxiolytic and mild nootropic effects of selank were demonstrated"
Medvedev and colleagues, 20158Phenazepam alone compared with Selank plus phenazepam; PubMed type randomized controlled trial70 patients with anxiety-phobic, hypochondriac and somatoform disorders (phenazepam 30, Selank plus phenazepam 40)Not stated in the recordEffect of phenazepam on HDRS "achieved earlier" with Selank; the combination decreased the level of phenazepam's undesirable side-effects
Uchakina and colleagues, 200820Blood cells in vitro, and serum from patients given SelankPatients with generalized anxiety disorder and neurasthenia (number not stated in the record); patients with depression and healthy controls in vitro10⁻⁷ M in vitro (the record prints "10-7 M"); 14 days in patientsIn vitro, Selank "completely suppressed gene expression by peripheral blood IL-6" of patients with depression but not of controls, while IL-6 concentration in culture rose (p<0,05); Th1/Th2 cytokine balance changed in patient serum
Panikratova and colleagues, 20209Resting-state fMRI before and 5 and 20 minutes after an injection of Selank, Semax or placebo52 healthy participants across Selank, Semax and placebo (group sizes not stated in the record)Single injection; dose not stated in the recordDifferences in functional connectivity between the right amygdala and regions of the right temporal cortex

Deeper analysis: Zozulia and colleagues, 2008

The authors compared Selank (30 patients) with medazepam (32 patients) in 62 patients with generalized anxiety disorder and neurasthenia, using psychometric scales (Hamilton, Zung, CGI) and a measurement of enkephalin activity in blood serum.7 The authors report that patients with these disorders "had the decreased level of tau(1/2) leu-enkephalin", and that the increase of this parameter during Selank treatment was seen "mostly in patients with GAD".7 The tau(1/2) is a value for leu-enkephalin, not for Selank, and the record states no comparator for the decreased level.7 The record gives no doses, scores, adverse events, funder, conflict-of-interest statement or limitations, and the author list includes Miasoedov NF.7

Deeper analysis: Medvedev and colleagues, 2014 and 2015

The 2014 report compared the anxiolytic effect and tolerability of Selank and phenazepam in 60 patients, and the record states: "Pronounced anxiolytic and mild nootropic effects of selank were demonstrated", and that the anxiolytic effect "lasted for a week after last receiving the peptide".6 Tolerability was a stated aim, and the record gives no tolerability result, group sizes, scores or doses.6 The 2015 report gave 30 patients phenazepam and 40 patients Selank plus phenazepam, assessing effect with HDRS, CGI and Spielberger scales and tolerability with the UKU scale.8 The authors report that "The combined treatment decreased the level of undesirable side-effects of phenazepam".8 Selank was given as an add-on, so the result is that of the combination against phenazepam alone, and the record gives no scores, doses, funder or limitations.8

Deeper analysis: Uchakina and colleagues, 2008

The authors measured immune responses to Selank in blood cells from patients with depression and from healthy controls in vitro, and in serum from patients with generalized anxiety disorder and neurasthenia given Selank for 14 days.20 They report that Th1/Th2 cytokine balance changed in the serum and write that the effects "suggest that selank can be used as a novel immunomodulator in patients with anxiety-asthenic disorders".20 The record gives no patient numbers, does not describe a control group for the 14-day measurements, and gives no funder, conflict-of-interest statement or limitations.20

Deeper analysis: Panikratova and colleagues, 2020

The authors, from the Mental Health Research Center, the Davidovskiy City Clinical Hospital and "Philips" (all in Moscow), tested the effects of Selank (described as an anxiolytic) and Semax (described as a nootropic) on whole-brain resting-state functional connectivity of predefined regions (the right and left amygdala and dorsolateral prefrontal cortex) in 52 healthy participants.9 Differences were reported between the right amygdala and a region in the right temporal cortex, and the authors write that the post hoc analysis defined "both general and specific effects of Selank and Semax".9 The record gives no group sizes, dose, route, anxiety scores, funder or limitations, and the author list includes Myasoedov NF.9

5

Doses reported in studies

The app's typical dose is 200 to 600 mcg. None of the records of the human reports states a dose, so the doses below come from animal and cell studies.

Table 5.1Doses reported in studies5 rows
SourceWhoDose and routeLengthNote
Volkova and colleagues, 2016310 rats per group (Selank, GABA, control), about 5 per time point300 µg/kg (6 µl) of Selank or GABA, intranasalSingle dose; genes read at 1 and 3 hoursAfter Selank or GABA, 45 genes changed at 1 hour and 22 at 3 hours (Selank 29 and 17, GABA 41 and 9)
Vasil'eva and colleagues, 201618BALB/c and C57BL/6 mice300 µg/kg a day, intranasal or intraperitoneal5 daysAnxiolytic and nootropic efficiency observed only in BALB/c mice
Kolomin and colleagues, 201414Mice100 µg/kg, intraperitonealSingle injection; spleen read from 30 minutes3-fold decrease in C3 mRNA at 30 minutes
Kolik and colleagues, 201915Outbred rats: 9-month-old rats without ethanol, and rats given 10% ethanol for 30 weeks (age not stated)0.3 mg/kg a day, intraperitoneal7 daysPrevented ethanol-induced increase in BDNF content (p<0.05)
Uchakina and colleagues, 200820Blood cells from patients with depression and from healthy controls10⁻⁷ M in culture (the record prints "10-7 M")In vitroIL-6 gene expression suppressed in cells from patients with depression but not controls

FDA's page states: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities".2 It adds that "FDA lacks important information regarding any safety issues raised by selank acetate administered to humans".2

In the 2015 report of 70 patients, the UKU scale recorded tolerability; the reported result concerns phenazepam's side effects, which were lower with Selank added, and the record states no adverse events for Selank itself.8 The records of the 2008 and 2014 reports state none either.7,6 Renke and Chinellato write, without figures, that "Uncommon adverse effects include mild daytime drowsiness or dry mouth" for Selank.5 In their introduction, citing earlier work by Seredenin and colleagues, Volkova and colleagues write that the effect of Selank is "not accompanied by the unwanted side effects of benzodiazepine tranquilizers such as amnesia, withdrawal, and dependence"; they give no outcome data for that statement, and the records of the human reports carry no dependence or withdrawal outcome.3

7

Bloodwork and markers

The app lists no markers for Selank. Zozulia and colleagues measured enkephalin activity in blood serum and report that patients with generalized anxiety disorder and neurasthenia "had the decreased level of tau(1/2) leu-enkephalin" (a value for leu-enkephalin, not for Selank, with no comparator stated), with an increase "mostly in patients with GAD" during Selank treatment.7 Uchakina and colleagues report changes in the Th1/Th2 cytokine balance in serum after 14 days of Selank.20

FDA's page on bulk drug substances for compounding that may present significant safety risks, current as of 22 April 2026, lists "Selank acetate (TP-7)" under "Bulk drug substances nominated but withdrawn".2 The page describes that list as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators".2

In Russia, Deigin and colleagues list Selank among peptide drugs developed there.4 Rahman and colleagues write that it is "approved in Russia for the treatment of anxiety", and Renke and Chinellato write that Semax and Selank "are approved as drugs in Russia", with "Selank for mild anxiety".22,5 Vanhee and colleagues, Sciensano (Belgium), report that two unknown suspicious preparations encountered at the end of 2017 and 2018 "contained the assumedly cognitive enhancing research peptides Selank and Semax", and that an online search, excluding the dark web, showed that "these kinds of nootropic research peptides are freely available either as lyophilized powder for injection purposes or are present in nasal sprays", a statement about the kind of peptide rather than Selank and Semax specifically.23

The text of the World Anti-Doping Agency's Prohibited List 2026, valid from 1 January 2026, does not contain the word Selank or the word tuftsin.24 Its S0 class covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".24 Pokrywka and colleagues, Biology of Sport, 2025, list Selank in a table of "Substances with 'unclear' status, including presumed to 'meet WADA criteria'", where the column headed "Similar chemical structure or similar biological effect(s) to (for presumed to 'meet WADA criteria')" names "tetracosactide (S2)" for Semax and is blank for Selank, so the table names no similar WADA-listed substance for Selank.25 Renke and Chinellato write of Semax and Selank: "WADA prohibits both, classifying them as peptides acting on the hormonal axis (category S2) or unapproved substances".5

The records read for the references give no half-life, bioavailability or time to peak for Selank in people, no human dose, and no subcutaneous data. The records of the four patient reports give no doses, no adverse event counts for Selank on its own, no funder and no limitations, and none of them gives scale scores.7,6,8,20 Vanhee and colleagues wrote in 2020 that Selank and Semax, "to our knowledge, have not completed any clinical trials", and Doyno and White wrote in 2021 that Selank is "poorly studied"; the Russian-language patient reports above predate both statements.23,21

What is the half-life of Selank?

The records read for the references report no half-life for Selank, and the app lists about 3 minutes. Zolotarev and colleagues, 2006, report that its pharmacokinetics were studied in brain tissue after intranasal administration, and the record states no values.17

What is Selank?

Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, a lengthened analog of the tuftsin fragment Thr-Lys-Pro-Arg.1,3

Is Selank FDA approved?

Renke and Chinellato's table lists Selank as "not yet FDA-approved".5 FDA's safety-risk page, current as of 22 April 2026, lists selank acetate (TP-7) under "Bulk drug substances nominated but withdrawn", substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators", and states that FDA lacks important information regarding any safety issues raised by it in humans.2

Is Selank approved in Russia?

Rahman and colleagues, 2026, write that Selank is "approved in Russia for the treatment of anxiety", and Renke and Chinellato, 2026, write that Semax and Selank "are approved as drugs in Russia", with "Selank for mild anxiety".22,5

Is Selank banned by WADA?

The World Anti-Doping Agency's Prohibited List 2026 does not contain the word Selank.24 Renke and Chinellato write that "WADA prohibits both" Semax and Selank, while Pokrywka and colleagues, 2025, list Selank among substances of "unclear" status.5,25

Has Selank been tested in humans?

Yes: three patient reports carry the clinical trial or randomized controlled trial publication type in PubMed, and an imaging study enrolled 52 healthy participants.7,6,8,9

How does Selank work?

The authors of the mechanism studies word the leading idea, allosteric modulation of GABA receptors, as a hypothesis.3 Vyunova and colleagues report positive allosteric modulation of [3H]GABA binding in membrane preparations, and Filatova and colleagues found no change in GABAergic gene mRNA levels with Selank alone in IMR-32 cells.1,10

What are the side effects of Selank?

FDA states that it lacks important information regarding any safety issues raised by selank acetate administered to humans.2 The records of the human reports state no adverse events for Selank on its own.8

Does Selank cause dependence or withdrawal?

The records of the human reports carry no dependence or withdrawal outcome.7,6,8 In their introduction, Volkova and colleagues cite earlier clinical work for the statement that the effect of Selank is "not accompanied by the unwanted side effects of benzodiazepine tranquilizers", and give no outcome data for it.3

12

References

  1. Vyunova TV, Andreeva L, Shevchenko K, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett 2018. PMID 30255741
  2. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). FDA safety-risk page
  3. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol 2016. PMC4757669
  4. Deigin VI, Poluektova EA, Beniashvili AG, et al. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics 2022. PMC9030433
  5. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Int J Mol Sci 2026. PMC13164565
  6. Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2014. PMID 25176261
  7. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova 2008. PMID 18454096
  8. Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova 2015. PMID 26356395
  9. Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci 2020. PMID 32342318
  10. Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol 2017. PMC5328971
  11. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol 2017. PMID 28280289
  12. Kost NV, Sokolov OIu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim 2001. PMID 11443939
  13. Zolotarev IuA, Sokolov OIu, Kost NV, et al. Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma. Bioorg Khim 2004. PMID 15344652
  14. Kolomin T, Morozova M, Volkova A, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol 2014. PMID 24291245
  15. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med 2019. PMID 31625062
  16. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci 2008. PMID 18841804
  17. Zolotarev IuA, Dadaian AK, Dolotov OV, et al. Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation. Bioorg Khim 2006. PMID 16637290
  18. Vasil'eva EV, Kondrakhin EA, Salimov RM, et al. Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Eksp Klin Farmakol 2016. PMID 29787664
  19. Ashmarin IP, Samonina GE, Lyapina LA, et al. Natural and hybrid ("chimeric") stable regulatory glyproline peptides. Pathophysiology 2005. PMID 15837162
  20. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2008. PMID 18577961
  21. Doyno CR, White CM. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol 2021. PMID 34396551
  22. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev 2026. PMC12753158
  23. Vanhee C, Francotte A, Janvier S, et al. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Test Anal 2020. PMID 31667971
  24. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
  25. Pokrywka A, Surala O, Grabowska K, et al. "Brain doping" substances: prohibited or not in sports? Biol Sport 2025. PMC12492343